NT-Pro BNP Predicts Myocardial Injury Post-vascular Surgery and is Reduced with CoQ10: A Randomized Double-Blind Trial

Asrar Khan, Debra K. Johnson, Selma Carlson, Laura Hocum-Stone, Rosemary F. Kelly, Amy A. Gravely, Mackenzi Mbai, Derrick L. Green, Steve Santilli, Santiago Garcia, Selcuk Adabag, Edward O. McFalls

Research output: Contribution to journalArticle

Abstract

Background: NT-Pro BNP levels provide incremental value in perioperative risk assessment prior to major noncardiac surgery. Whether they can be pharmacologically modified in patients prior to an elective vascular operation is uncertain. Methods: A double-blind, randomized controlled trial was implemented at a single institution. Patients were screened during their preoperative vascular clinic appointment and randomly assigned to CoQ10 (400 mg per day) versus Placebo for 3 days prior to surgery. Biomarkers, including NT-Pro BNP, troponin I and C-reactive protein were obtained prior to and following surgery for up to 48 hours. The primary endpoint was postoperative NT-Pro BNP levels, and secondary endpoint measures included myocardial injury, defined by an elevated cardiac troponin level and length of stay. Results: One hundred and twenty-three patients were randomized to receive either CoQ10 (N = 62) versus Placebo (N = 61) for 3 days before vascular surgery. Preoperative cardiac risks included ischemic heart disease (N = 52), CHF (N = 12), stroke (N = 23), and diabetes mellitus (N = 48) and the planned vascular procedures were infrainguinal (N = 78), carotid (N = 36), and intraabdominal (N = 9). There were no intergroup differences in these clinical variables. NT-Pro BNP levels (median; IQs) in the CoQ10 and Placebo groups were 179 (75–347) and 217 (109–585) pg/ml, respectively, (P = 0.08) preoperatively, and 397 (211–686) and 591 (288–1,433) pg/ml respectively, (P = 0.01) at 24 hours following surgery. Patients with an elevated NT-Pro BNP had a higher incidence of myocardial injury, (58% vs. 20%; P < 0.01) and a longer hospital stay (4.4 ± 3.8 vs. 2.8 ± 3.2 days; P < 0.02) compared with individuals without an elevated NT-Pro BNP level. Conclusions: NT-Pro BNP levels predict adverse events post-vascular surgery and are lowered in those patients assigned to preoperative administration of CoQ10. Trial Registration: clinicaltrials.gov Identifier: NCT03956017. Among patients undergoing elective vascular surgery, 123 patients were randomized to either CoQ10 (400 mg/day) versus placebo for three days preoperatively. NT-Pro BNP levels (median; IQs) in the CoQ10 and Placebo groups were 179 (75–347) and 217 (109–585) pg/ml, respectively, (P = 0.08) preoperatively, and 397 (211–686) and 591 (288–1,433) pg/ml, respectively, (P = 0.01) post-surgery. Patients with an elevated NT-Pro BNP had a higher incidence of myocardial injury (58% vs. 20%; P < 0.01) and a longer hospital stay (4.4 ± 3.8 vs. 2.8 ± 3.2 days; P < 0.02) compared with individuals without an NT-Pro BNP elevation. In conclusion, BNP predicts adverse outcomes and can be reduced with preoperative CoQ10.

Original languageEnglish (US)
Pages (from-to)292-302
Number of pages11
JournalAnnals of Vascular Surgery
Volume64
DOIs
StatePublished - Apr 2020

PubMed: MeSH publication types

  • Journal Article

Fingerprint Dive into the research topics of 'NT-Pro BNP Predicts Myocardial Injury Post-vascular Surgery and is Reduced with CoQ<sub>10</sub>: A Randomized Double-Blind Trial'. Together they form a unique fingerprint.

  • Cite this

    Khan, A., Johnson, D. K., Carlson, S., Hocum-Stone, L., Kelly, R. F., Gravely, A. A., Mbai, M., Green, D. L., Santilli, S., Garcia, S., Adabag, S., & McFalls, E. O. (2020). NT-Pro BNP Predicts Myocardial Injury Post-vascular Surgery and is Reduced with CoQ10: A Randomized Double-Blind Trial. Annals of Vascular Surgery, 64, 292-302. https://doi.org/10.1016/j.avsg.2019.09.017